Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00024171
DRKS00024171
Completed
Not Applicable

Investigation of the humoral and cellular immunity against SARS-CoV2 in patients after kidney transplantation in pandemic times - CORENO

niversitätsklinikum Köln0 sites46 target enrollmentApril 19, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsU07.1COVID-19, virus identified

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
U07.1
Sponsor
niversitätsklinikum Köln
Enrollment
46
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 19, 2021
End Date
September 12, 2022
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
niversitätsklinikum Köln

Eligibility Criteria

Inclusion Criteria

  • •Patients after kidney transplantation:
  • •\- All patients over the age of 16 who are regularly treated in our outpatient clinics
  • •\- Present written declaration of consent.
  • •Patients end stage kidney disease:
  • •\- All patients who are preparing for a kidney transplant at our center. The minimum age is set at 16 years.
  • •\- Present written declaration of consent.
  • •\- Controll group:
  • •Present written declaration of consent.

Exclusion Criteria

  • •\- Persons who are in a dependent / working relationship with the examiners, in particular employees of the clinics and institutes involved
  • •\- Current infection with SARS\-CoV2 (positive PCR result)
  • •\- Inability to consent, e.g. due to language barriers or mental illness
  • •\- Placement in an institution based on a judicial or administrative order
  • •\- Controll group: people who suffer from chronic kidney disease chronic immunosuppression

Outcomes

Primary Outcomes

Not specified

Similar Trials

Not yet recruiting
Not Applicable
Study to the humoral and cellular immuneresponse after influenzavaccination in patients with metastasized RCC or GIST treated with a tyrosine kinase inhibitor(sunitinib or sorafenib)GISTkidney cancer10038363
NL-OMON32710niversitair Medisch Centrum Sint Radboud75
Active, not recruiting
Not Applicable
Characterisation of humoral and cellular immunity of low- and high-responder after TBE vaccinatio
EUCTR2008-005800-24-ATMedizinische Universität Wien, Institut für Spezifische Prophylaxe und Tropenmedizin84
Active, not recruiting
Phase 1
Characterization of humoral and cellular immunity for tick-borne encephalitis (TBE) vaccination in allogeneic blood and marrow graft recipients: a pilot study
EUCTR2011-002928-41-ATMed. Uni. Wien, Klinik für Innere I52
Active, not recruiting
Phase 1
Detailed analysis of the immune responses after vaccination against Japanese Encephalitis in the elderly.
EUCTR2010-020450-33-ATInstitute of Specific Prophylaxis and Tropical Medicine60
Active, not recruiting
Not Applicable
A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac) - mgus-vacc respons
EUCTR2010-022693-14-NLuniversity medical centre groningen